TRDA · Entrada Therapeutics, Inc.

$7.46 +0.01 (+0.13%) At close · Aug 14

Market Cap

$290.47M

38.94M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dipal Doshi	Chief Executive Officer	$635,000	—	$1,387,428	$1,452,059	$349,250	$14,000	$3,837,737
Natarajan Sethuraman Ph. D	President of Research and Development	$520,000	—	$725,952	$760,363	$234,000	$14,000	$2,254,315
Nathan J. Dowden	President and Chief Operating Officer	$499,200	—	$725,952	$760,363	$224,640	$13,342	$2,223,497

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dipal Doshi	Chief Executive Officer	$610,000	—	$1,437,531	$1,494,662	$335,510	$13,800	$3,891,503
Nathan J. Dowden	President and Chief Operating Officer	$480,000	—	$1,278,263	$472,615	$216,010	$13,800	$2,460,688
Natarajan Sethuraman Ph. D	President of Research and Development	$493,232	—	$605,493	$630,015	$221,980	$11,980	$1,962,700

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dipal Doshi	Chief Executive Officer	$585,000	—	$1,373,319	$1,393,934	$370,013	$13,200	$3,735,466
Natarajan Sethuraman Ph. D	President of Research and Development	$456,501	—	$392,772	$398,384	$224,598	$13,200	$1,485,455
Nathan J. Dowden	President and Chief Operating Officer	$456,501	—	$392,772	$398,384	$224,598	$13,200	$1,485,455

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dipal Doshi	Chief Executive Officer	$565,000	—	$546,618	$2,042,370	$324,875	$12,200	$3,491,063
Natarajan Sethuraman Ph. D	Chief Scientific Officer	$440,000	—	$203,529	$760,786	$202,400	$12,200	$1,618,915
Nathan J. Dowden	President and Chief Operating Officer	$440,000	—	$186,916	$698,873	$202,400	$12,200	$1,540,389

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dipal Doshi	President and Chief Executive Officer	$425,057	$117,500	—	$4,742,292	$233,050	$12,500	$5,530,399
Natarajan Sethuraman Ph. D	Chief Scientific Officer	$382,939	$60,000	—	$3,684,745	$178,930	—	$4,306,614
Nathan J. Dowden	Chief Operating Officer	$378,532	$50,000	—	$1,706,565	$176,920	—	$2,312,017

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Natarajan Sethuraman Ph. D	Chief Scientific Officer	$359,625	—	—	$93,965	$126,175	—	$579,765
Nathan J. Dowden	Chief Operating Officer	$354,488	—	—	$82,636	$124,373	—	$561,497

Executive changes

Person	Role	Change	Effective	Filed
Bernhardt Zeiher, M.D.	Class II director	Appointed	2026-06-10	2026-06-10
Peter S. Kim, Ph.D.	Class II director	Appointed	2026-06-10	2026-06-10
Maha Radhakrishnan	Class III director	Appointed	2025-06-01	2025-06-03
Nathan J. Dowden	President	Appointed	2024-01-01	2024-01-03
Kush M. Parmar, M.D., Ph.D.	member and the Chair of the Compensation Committee	Appointed	2023-12-05	2023-12-06
Gina Chapman	member of the Audit Committee	Appointed	2023-12-05	2023-12-06
John F. Crowley	member of the Board of Directors	Resigned	2023-12-05	2023-12-06
Gina Chapman	Class III director	Appointed	2023-09-01	2023-08-10
Bernhardt Zeiher, M.D.	Class II director	Appointed	—	2023-06-08
Peter S. Kim, Ph.D.	Class II director	Appointed	—	2023-06-08
Todd Foley	member of the Company's Board of Directors	Resigned	2023-06-07	2023-06-08
Bernhardt Zeiher, M.D.	Class II director	Appointed	2023-04-04	2023-04-04

Key facts CIK 1689375 CUSIP 29384C108 13F (30d) 123 filings 122 filers Visit website Investor relations